Molbio Diagnostics jumps as Jefferies starts with Buy rating
In short
Molbio Diagnostics shares jumped after Jefferies started coverage with a Buy rating and called it a high-conviction top pick.
Jefferies set a Rs 1,600 target price, which is 27% above Tuesday’s close and nearly 98% above the Rs 807 IPO price. The report does not say how long the gain will last.
What the reporting says
Molbio Diagnostics shares jumped after Jefferies initiated coverage with a Buy rating and called it a high-conviction top pick. The brokerage set a Rs 1,600 target price, implying 27% upside from Tuesday’s close and nearly 98% above the Rs 807 IPO price. The stock had listed at a 21% premium at Rs 980, while the source does not say whether the rally held.
Why it matters
Molbio Diagnostics shares rose after Jefferies initiated coverage with a Buy rating and named it a high-conviction top pick. The brokerage set a Rs 1,600 target price, which the report says implies 27% upside from Tuesday’s close and nearly 98% above the company’s Rs 807 IPO price. The immediate market effect is a sentiment boost for the stock, though the durability of the move is unknown.